down arrow

D. Western Therapeutics Institute, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3548740004
JPY
99.00
-3 (-2.94%)

Dec 11

TKS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Solasia Pharma KK
Nippon Chemiphar Co., Ltd.
BrightPath Biotherapeutics Co., Ltd.
Wakamoto Pharmaceutical Co., Ltd.
D. Western Therapeutics Institute, Inc.
Pharmarise Holdings Corp.
RaQualia Pharma, Inc.
Renascience, Inc.
SymBio Pharmaceuticals Ltd.
CanBas Co., Ltd.
Delta-Fly Pharma, Inc.
Why is D. Western Therapeutics Institute, Inc. ?
1
Poor Management Efficiency with a low ROE of 0%
  • The company has reported losses. Due to this company has reported negative ROE
2
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
3
The company has declared Negative results for the last 12 consecutive quarters
  • INTEREST(9M) At JPY 5.65 MM has Grown at 103.38%
  • NET SALES(9M) At JPY 295.91 MM has Grown at -12.43%
  • RAW MATERIAL COST(Y) Grown by 8.45% (YoY)
4
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 3.13%, its profits have fallen by -4.2%
5
Underperformed the market in the last 1 year
  • The stock has generated a return of 3.13% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 28.54%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is D. Western Therapeutics Institute, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
D. Western Therapeutics Institute, Inc.
3.12%
0.10
104.87%
Japan Nikkei 225
28.54%
1.11
25.75%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
4.08%
EBIT Growth (5y)
-261.93%
EBIT to Interest (avg)
-152.17
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.63
Sales to Capital Employed (avg)
0.23
Tax Ratio
0.14%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.43
EV to EBIT
-4.65
EV to EBITDA
-4.88
EV to Capital Employed
12.96
EV to Sales
10.36
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-278.61%
ROE (Latest)
-105.85%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company
NET PROFIT(9M)

Higher at JPY -881.04 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 4.13%

-21What is not working for the Company
INTEREST(9M)

At JPY 5.65 MM has Grown at 103.38%

NET SALES(9M)

At JPY 295.91 MM has Grown at -12.43%

RAW MATERIAL COST(Y)

Grown by 8.45% (YoY

CASH AND EQV(HY)

Lowest at JPY 2,189.17 MM

Here's what is working for D. Western Therapeutics Institute, Inc.
Net Profit
Higher at JPY -317.93 MM
than preceding 12 month period ended Jun 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (JPY MM)

Debtors Turnover Ratio
Highest at 4.13%
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for D. Western Therapeutics Institute, Inc.
Net Sales
At JPY 76.48 MM has Fallen at -34%
over average net sales of the previous four periods of JPY 115.88 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (JPY MM)

Net Sales
Lowest at JPY 76.48 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (JPY MM)

Interest
Highest at JPY 2.08 MM
in the last five periods and Increased by 9.46% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Cash and Eqv
Lowest at JPY 2,189.17 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost
Grown by 8.45% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."